{"database": "lobbying", "table": "lobbying_activities", "rows": [[668960, "c65383ae-8153-414b-b5f4-de16517ea45c", "Q3", "INVARIANT LLC", 314237, "ELI LILLY AND COMPANY", 2008, "third_quarter", "MED", "H.R. 5629, Pathway for Biosimilars Act;  H.R. 1038/S. 623, Access to Life-Saving Medicine Act;  H.R. 1956, Patient Protection and Innovative Biologic Medicines Act of 2007;  S. 1505, Affordable Biologics for Consumers Act;  S. 1695, Biologics Price Competition and Innovation Act of 2007, as they pertain to the term of data exclusivity for biologic drugs.", "HOUSE OF REPRESENTATIVES", 50000, null, 0, 0, "2008-10-16T11:24:21-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["668960"], "units": {}, "query_ms": 2.0044060656800866, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}